Summary
This narrative review synthesises current knowledge on next-generation probiotics (NGPs) isolated from the human gut microbiome, assessing their potential for precision functional food development. The authors analyse representative commensal species and their capacity to support intestinal health through epithelial barrier maintenance, short-chain fatty acid production, and immune modulation, whilst identifying critical barriers to commercialisation: oxygen sensitivity, poor viability under processing stress, and inconsistent global regulatory frameworks that classify NGPs as either live biotherapeutic products or Novel Foods.
Regional applicability
The review addresses global regulatory classification challenges but does not focus on United Kingdom-specific policy or practice. Its conclusions regarding regulatory harmonisation and delivery system innovation would be directly relevant to UK functional food manufacturers and regulators, but transferability depends on adoption of harmonised EU/UK frameworks for live biotherapeutic products and Novel Food assessment.
Key measures
Classification of next-generation probiotics; mechanisms of action (intestinal epithelial integrity, short-chain fatty acid synthesis, immune modulation); viability under processing stress and digestive conditions; regulatory classification as live biotherapeutic products or Novel Foods
Outcomes reported
The review evaluated representative next-generation probiotic species for their capacity to maintain intestinal epithelial integrity, synthesise short-chain fatty acids, and modulate immune responses. It examined technological and regulatory challenges limiting their commercial application in functional foods.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.